Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when PCVX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: PCVX Vaxcyte, Inc. 8-K

Vaxcyte appoints John Markels to board as Heath Lukatch retires after 8+ years

Filed July 15, 2026 · Period ending July 13, 2026 · ~1 min read

3 key changes

Key Changes

  • medium

    Heath Lukatch retired from the board effective July 16, 2026, after more than eight years of service. The filing states his retirement was not due to any disagreement or dispute with the company.

    Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
  • medium

    John Markels was appointed as a Class II director effective July 16, 2026, with a term through the 2028 annual meeting. He will serve on both the Audit Committee and Compensation Committee.

    Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
  • low

    Dr. Markels qualifies as an independent director under Nasdaq rules and will receive standard non-employee director compensation, including an annual equity grant valued at $430,000.

    Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →

Summary

Vaxcyte disclosed a routine board transition: Heath Lukatch retired after more than eight years of service, and John Markels was appointed to fill the vacancy. The filing explicitly confirms Dr. Lukatch's departure was amicable, with no disagreement or dispute with the company. Dr. Markels joins as a Class II director with a term through 2028 and will serve on two critical oversight committees—Audit and Compensation.

His appointment maintains board continuity and committee coverage. The company confirmed his independence under Nasdaq listing standards and disclosed standard director compensation, including a $430,000 annual equity grant. This is a straightforward governance matter with no material impact on operations or strategy.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jul 16, 2026 · How we verify